Section of Immunology & Joint Immunology Program, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Immunol. 2021 Jul 5;12:683249. doi: 10.3389/fimmu.2021.683249. eCollection 2021.
Macrophages, a major subset of innate immune cells, are main infiltrating cells in the kidney in lupus nephritis. Macrophages with different phenotypes exert diverse or even opposite effects on the development of lupus nephritis. Substantial evidence has shown that macrophage M2 polarization is beneficial to individuals with chronic kidney disease. Further, it has been reported that PD-1 ligands (PD-Ls) contribute to M2 polarization of macrophages and their immunosuppressive effects. Total glucosides of paeony (TGP), originally extracted from Radix Paeoniae Alba, has been approved in China to treat some autoimmune diseases. Here, we investigated the potentially therapeutic effects of TGP on lupus nephritis in a pristane-induced murine model and explored the molecular mechanisms regulating macrophage phenotypes. We found that TGP treatment significantly improved renal function by decreasing the urinary protein and serum creatinine, reducing serum anti-ds-DNA level and ameliorating renal immunopathology. TGP increased the frequency of splenic and peritoneal F4/80CD11bCD206 M2-like macrophages with no any significant effect on F4/80CD11bCD86 M1-like macrophages. Immunofluorescence double-stainings of the renal tissue showed that TGP treatment increased the frequency of F4/80Arg1 subset while decreasing the percentage of F4/80iNOS subset. Importantly, TGP treatment increased the percentage of both F4/80CD11bPD-L1 and F4/80CD11bPD-L2 subsets in spleen and peritoneal lavage fluid as well as the kidney. Furthermore, TGP augmented the expressions of CD206, PD-L2 and phosphorylated STAT6 in IL-4-treated Raw264.7 macrophages while its effects on PD-L2 were abolished by pretreatment of the cells with an inhibitor of STAT6, AS1517499. However, TGP treatment did not affect the expressions of STAT1 and PD-L1 in Raw264.7 macrophages treated with LPS/IFN-γ , indicating a possibly indirect effect of TGP on PD-L1 expression on macrophages . Thus, for the first time, we demonstrated that TGP may be a potent drug to treat lupus nephritis by inducing F4/80CD11bCD206 and F4/80CD11bPD-L2 macrophages through IL-4/STAT6/PD-L2 signaling pathway.
巨噬细胞是先天免疫细胞的主要亚群之一,是狼疮性肾炎肾脏中的主要浸润细胞。具有不同表型的巨噬细胞对狼疮性肾炎的发展产生不同甚至相反的影响。大量证据表明,巨噬细胞 M2 极化有利于慢性肾脏病患者。此外,有报道称 PD-1 配体(PD-Ls)有助于巨噬细胞的 M2 极化及其免疫抑制作用。白芍总苷(TGP)最初从白芍中提取,已在中国获准用于治疗某些自身免疫性疾病。在这里,我们在芴诱导的小鼠模型中研究了 TGP 治疗狼疮性肾炎的潜在治疗效果,并探讨了调节巨噬细胞表型的分子机制。我们发现,TGP 通过降低尿蛋白和血清肌酐、降低血清抗 ds-DNA 水平和改善肾脏免疫病理学来显著改善肾功能。TGP 增加了脾和腹腔 F4/80CD11bCD206 M2 样巨噬细胞的频率,而对 F4/80CD11bCD86 M1 样巨噬细胞没有任何显著影响。肾组织免疫荧光双重染色显示,TGP 治疗增加了 F4/80Arg1 亚群的频率,同时降低了 F4/80iNOS 亚群的百分比。重要的是,TGP 治疗增加了脾和腹腔灌洗液以及肾脏中 F4/80CD11bPD-L1 和 F4/80CD11bPD-L2 亚群的百分比。此外,TGP 增强了 IL-4 处理的 Raw264.7 巨噬细胞中 CD206、PD-L2 和磷酸化 STAT6 的表达,而在用 STAT6 抑制剂 AS1517499 预处理细胞后,其对 PD-L2 的作用被消除。然而,TGP 治疗对 LPS/IFN-γ 处理的 Raw264.7 巨噬细胞中 PD-L1 的表达没有影响,表明 TGP 对巨噬细胞 PD-L1 表达的可能是间接影响。因此,我们首次证明,TGP 通过 IL-4/STAT6/PD-L2 信号通路诱导 F4/80CD11bCD206 和 F4/80CD11bPD-L2 巨噬细胞,可能成为治疗狼疮性肾炎的有效药物。